W Elger

No ORCID on file · 16 papers in corpus
lab-animal 2023
Frontiers in endocrinology ·doi:10.3389/fendo.2023.1201547

INTRODUCTION: The pharmacological target for progesterone, different progestins, and Selective Progesterone Receptor Modulators (SPRMs) is the nuclear progesterone receptor (PR). EC313 is a new member of a subgroup of SPRMs, mesoprogestins,…

other 2019
Human reproduction open ·doi:10.1093/hropen/hoz027

STUDY QUESTION: What is the safety and efficacy profile during long-term (12-24 months) uninterrupted treatment with the selective progesterone receptor modulator asoprisnil, 10 and 25 mg in women with heavy menstrual bleeding (HMB) associa…

review 2006
Reproductive biology and endocrinology : RB&E ·doi:10.1186/1477-7827-4-s1-s8

Selective progesterone receptor modulators (SPRMs) represent a new class of progesterone receptor ligands that exert clinically relevant tissue-selective progesterone agonist, antagonist, partial, or mixed agonist/antagonist effects on vari…

review 2005
Endocrine Reviews ·doi:10.1210/er.2005-0001

Selective progesterone receptor modulators (SPRMs) represent a new class of progesterone receptor ligands. SPRMs exert clinically relevant tissue-selective progesterone agonist, antagonist, or mixed agonist/antagonist effects on various pro…

rct 2005
Human Reproduction ·doi:10.1093/humrep/deh738

BACKGROUND: Asoprisnil (J867) is a novel selective progesterone receptor modulator (SPRM) that exhibits partial agonist and antagonist activities and tissue selective effects. This double-blind, dose-escalation study was conducted to evalua…

2004
·doi:10.1016/j.fertnstert.2004.07.212
review 2003
Steroids ·doi:10.1016/j.steroids.2003.09.008

Asoprisnil is a novel selective steroid receptor modulator that shows unique pharmacodynamic effects in animal models and humans. Asoprisnil, its major metabolite J912, and structurally related compounds represent a new class of progesteron…

review 2002
Annals of the New York Academy of Sciences ·doi:10.1111/j.1749-6632.2002.tb02798.x

Endometriosis, the presence of endometrial tissue outside the uterus, is a progressive, estrogen-dependent disease and occurs nearly exclusively in menstruating women of reproductive age. Pain syndrome, however, represents the major clinica…

review 1999
·doi:10.3109/13625189909085259

Dienogest is the first non-alkylated 19-norprogestin on the market. This so-called hybrid progestin combines the typical qualities of the modern 19-norprogestins with those of natural progesterone and synthetic hydroxyprogesterone derivativ…

review 1998
Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie ·doi:10.1016/s0940-2993(98)80034-1

The strong hepatic estrogenic actions of ethinylestradiol (EE) are very likely to be the cause of the cardiovascular morbidity related to the use of combined oral contraceptives (COCs). This survey presents results of EE replacement in COCs…

1995
·doi:10.1515/9783112422168-010
1995
·doi:10.1515/9783110813210-010
1995
·doi:10.1515/9783110813210-004
1995
·doi:10.1515/9783112422168-004
lab-animal 1995
Steroids ·doi:10.1016/0039-128x(94)00043-c

Mifepristone (RU 486), used clinically for the termination of early pregnancy, and its acetyl and 13-retro (13 alpha) analogs show potent antiproliferative effects against estrogen-dependent human breast tumors and endometriosis. However, t…

lab-animal 1991
Endocrinology ·doi:10.1210/endo-129-1-312

There is evidence from previous studies that progesterone antagonists (antigestagens) modify estrogen responses at endometrial and myometrial levels without having affinity to the estrogen receptor (ER). The purpose of the present study was…